Free κ and λ Light Chains Plus Ratio, Quantitative, Urine (Serial Monitor)
Use
The Free κ and λ Light Chains Plus Ratio, Quantitative, Urine test is utilized for the long-term serial monitoring of free kappa and lambda light chains in urine. It is useful in assessing and managing patients with conditions such as multiple myeloma and other monoclonal gammopathies. The quantitative measurement aids in the diagnosis, evaluation of disease progression, and response to therapy in affected individuals, by providing an important biomarker in the detection of abnormal protein levels characteristic of these diseases.
Special Instructions
For accurate longitudinal analysis, consistency in assay methodology is strongly recommended. Variability between different assay systems can affect patient monitoring outcomes. Ensure consistency by using this test consistently for monitoring each specific patient to avoid discrepancies in results. Mandatory submission of the patient's Social Security number is required for effective serial monitoring. To order without serial monitor functionality, please reference test 121228.
Limitations
Values obtained with different assay methods should not be used interchangeably in serial testing as they may produce inconsistent results. While this test provides crucial information in monitoring monoclonal gammopathies, results should not be interpreted as absolute indicators of malignant disease in isolation. Various factors, including technical variability and biological factors, could influence the test outcomes; thus, clinical correlation is necessary to confirm findings.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 38176-4
- 38178-0
- 41759-2
- 38176-4
- 38178-0
- 41759-2
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
Not provided
Minimum Volume
Not provided